Quest Diagnostics: Beat Down After Beating Q2 Estimates

In my previous analysis of Quest Diagnostics (NYSE:DGX), I examined their Q2 2023 eamings report, which produced a slight beat on EPS and revenue. The company did report a slight decline in COVID-related revenues, however, they were able to log a 9.5% year-over-year growth in revenue. At that time, I believed that Quest's efforts in expanding its clinical services, and amassing acquisitions, were going to lead to additional growth. As a result, I was bullsh on DGX, especially considering Quest's healthy div ...